TD Cowen Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $65
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has initiated coverage on Protagonist Therapeutics with a Buy rating and set a price target of $65.
September 24, 2024 | 9:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen has initiated coverage on Protagonist Therapeutics with a Buy rating and a price target of $65, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $65 by TD Cowen suggests a positive sentiment towards Protagonist Therapeutics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100